GenSight Biologics S.A. GSGTF
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 0.59% | -652.62% | |||
| Total Other Revenue | -0.58% | -7.34% | |||
| Total Revenue | 0.60% | -242.43% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 0.60% | -242.43% | |||
| SG&A Expenses | -0.59% | 11.32% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.59% | 58.51% | |||
| Operating Income | 0.59% | -101.13% | |||
| Income Before Tax | 0.59% | -103.79% | |||
| Income Tax Expenses | 0.00% | -73.91% | |||
| Earnings from Continuing Operations | 0.59% | -103.65% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.59% | -103.65% | |||
| EBIT | 0.59% | -101.13% | |||
| EBITDA | 0.59% | -103.82% | |||
| EPS Basic | 0.37% | -53.71% | |||
| Normalized Basic EPS | 0.60% | -54.13% | |||
| EPS Diluted | 0.37% | -53.71% | |||
| Normalized Diluted EPS | 0.60% | -54.13% | |||
| Average Basic Shares Outstanding | 0.00% | 32.47% | |||
| Average Diluted Shares Outstanding | 0.00% | 32.47% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||